Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Control,open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker

Next Previous
Trial Profile

A Randomized, Control,open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilostazol (Primary) ; Probucol (Primary)
  • Indications Arteriosclerosis obliterans; Embolism and thrombosis
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 16 Jan 2010 Planned end date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov
  • 27 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
  • 22 Jan 2009 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top